Technology
Neutral
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Breaking news from global financial markets
4 days ago
Read More
4 days ago
1,490
4 days ago
4,672
4 days ago
2,905
4 days ago
550
Ziff Davis Becomes Oversold (ZD)
Technology
4 days ago
1,166
4 days ago
2,268
4 days ago
2,808
4 days ago
4,134
4 days ago
2,616
4 days ago
4,697
4 days ago
3,078
4 days ago
4,195
Arista Networks  Non-GAAP EPS of $0.75 beats by $0.04, revenue of $2.31B beats by $40M
Technology
4 days ago
2,925
4 days ago
3,197
Tech valuations are ‘pretty reasonable’ given growth rates despite drop in big tech – strategist
Technology
4 days ago
2,169
Stocks Retreat on Valuation Concerns
Technology
4 days ago
4,157
4 days ago
4,707